(c) 2024 PillSync.com

Rosuvastatin calcium 10 MG Oral Tablet

1 INDICATIONS AND USAGE Rosuvastatin calcium tablets are an HMG Co-A reductase inhibitor indicated for: pediatric patients 7 to 17 years of age with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, non-HDL-C and Apo-B as an adjunct to diet, either alone or with other lipid-lowering treatments ( 1.2 ) adult patients with hypertriglyceridemia as an adjunct to diet ( 1.3 ) adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet ( 1.4 ) adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB ( 1.5 ) Limitations of use ( 1.8 ): Rosuvastatin calcium tablets have not been studied in Fredrickson Type I and V dyslipidemias. 1.2 Pediatric Patients with Familial Hypercholesterolemia Rosuvastatin calcium tablets are indicated as an adjunct to diet to: ● reduce LDL-C, Total-C, non-HDL-C and Apo-B in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis). Pediatric use information for patients ages 8 to less than 10 years is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1. 3 Hypertriglyceridemia Rosuvastatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1. 4 primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1. 5 Adult Patients with homozygous familial hypercholesterolemia Rosuvastatin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and Apo-B in adult patients with homozygous familial hypercholesterolemia. 1. 8 Limitations of Use Rosuvastatin calcium tablets have not been studied in Fredrickson Type I and V dyslipidemias.

Actavis Pharma, Inc.


4 years ago ROUND PINK RU10 Rosuvastatin calcium 10 MG Oral Tablet

ROUND PINK RU10

4 years ago ROUND PINK RU10 Rosuvastatin calcium 10 MG Oral Tablet

RU10 ROUND PINK

16 HOW SUPPLIED/STORAGE AND HANDLING Rosuvastatin calcium tablets are supplied as: 5 mg tablets: yellow, round convex shaped coated tablets with “RU5” on one side and blank on the other side. NDC 16252-615-30 bottles of 30 NDC 16252-615-90 bottles of 90 NDC 16252-615-50 bottles of 500 10 mg tablets: pink, round convex shaped coated tablets with “RU10” on one side and blank on the other side. NDC 16252-616-30 bottles of 30 NDC 16252-616-90 bottles of 90 NDC 16252-616-50 bottles of 500 20 mg tablets: pink, round convex shaped coated tablets with “RU20” on one side and blank on the other side. NDC 16252-617-30 bottles of 30 NDC 16252-617-90 bottles of 90 NDC 16252-617-50 bottles of 500 40 mg tablets: pink, oval shaped coated tablets with “RU40” on one side and blank on the other side. NDC 16252-618-30 bottles of 30 NDC 16252-618-90 bottles of 90 NDC 16252-618-50 bottles of 500 Storage Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature]. Protect from moisture.


More pills like ROUND RU10












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site